ArticleNature reviews. Clinical oncology2017
Haematological cancer: Idelalisib for CLL - risky benefit.
Diana RomeroPubMed ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it
ArticleNature reviews. Clinical oncology2017
Diana RomeroPubMed ↗Publisher ↗
No numbers read from the abstract.